Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
9.03
-1.98 (-17.98%)
Jun 10, 2026, 10:51 AM EDT - Market open
Eloxx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 6.36 | 4.79 | 0.11 | 1.13 | 19.21 | 42.27 |
Cash & Short-Term Investments | 6.36 | 4.79 | 0.11 | 1.13 | 19.21 | 42.27 |
Cash Growth | 33.26% | 4210.81% | -90.21% | -94.10% | -54.56% | 71.35% |
Accounts Receivable | - | - | 2.36 | - | - | - |
Other Receivables | - | - | 0.36 | - | - | - |
Receivables | - | - | 2.72 | - | - | - |
Prepaid Expenses | 0.03 | 0.14 | 0.07 | 0.15 | 0.09 | 0.12 |
Restricted Cash | 0.01 | 0.01 | 0.01 | 0.22 | 0.26 | 0.3 |
Other Current Assets | 2.1 | 0.34 | 0.08 | 0.05 | 0.57 | 0.79 |
Total Current Assets | 8.5 | 5.27 | 2.98 | 1.55 | 20.13 | 43.48 |
Property, Plant & Equipment | - | - | - | 0.16 | 0.99 | 1.66 |
Total Assets | 8.5 | 5.27 | 2.98 | 1.71 | 21.12 | 45.14 |
Accounts Payable | 3.03 | 2.71 | 5.35 | 5.7 | 3.02 | 1.38 |
Accrued Expenses | 1.24 | 1.65 | 2 | 1.21 | 2.8 | 4.2 |
Short-Term Debt | 11.82 | 11.82 | 13.35 | 12.97 | 12.54 | 3.72 |
Current Portion of Long-Term Debt | - | 1 | 6.52 | 2.22 | 3.98 | - |
Current Portion of Leases | - | - | 0 | 0.13 | 0.71 | 0.66 |
Other Current Liabilities | - | - | 0.1 | 0.47 | 0.05 | - |
Total Current Liabilities | 16.09 | 17.18 | 27.31 | 22.7 | 23.09 | 9.96 |
Long-Term Debt | - | - | - | 1.61 | 8.56 | 12 |
Long-Term Leases | - | - | - | 0 | 0.14 | 0.8 |
Total Liabilities | 16.09 | 17.18 | 27.31 | 24.31 | 31.78 | 22.76 |
Common Stock | 0.05 | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 |
Additional Paid-In Capital | 296.7 | 288.63 | 270.22 | 268.81 | 263.71 | 262.88 |
Retained Earnings | -304.33 | -300.58 | -294.59 | -291.44 | -274.39 | -238.32 |
Treasury Stock | - | - | - | - | - | -2.19 |
Total Common Equity | -7.58 | -11.91 | -24.34 | -22.6 | -10.66 | 22.38 |
Shareholders' Equity | -7.58 | -11.91 | -24.34 | -22.6 | -10.66 | 22.38 |
Total Liabilities & Equity | 8.5 | 5.27 | 2.98 | 1.71 | 21.12 | 45.14 |
Total Debt | 11.82 | 12.82 | 19.87 | 16.93 | 25.92 | 17.18 |
Net Cash (Debt) | -5.46 | -8.03 | -19.76 | -15.8 | -6.71 | 25.09 |
Net Cash Growth | - | - | - | - | - | 112.14% |
Net Cash Per Share | -2.56 | -7.15 | -57.82 | -67.60 | -34.08 | 157.78 |
Filing Date Shares Outstanding | 0.69 | 0.46 | 0.34 | 0.23 | 0.2 | 0.2 |
Total Common Shares Outstanding | 0.46 | 0.44 | 0.34 | 0.23 | 0.2 | 0.2 |
Working Capital | -7.58 | -11.91 | -24.34 | -21.15 | -2.96 | 33.53 |
Book Value Per Share | -16.44 | -27.34 | -71.22 | -96.70 | -54.13 | 113.66 |
Tangible Book Value | -7.58 | -11.91 | -24.34 | -22.6 | -10.66 | 22.38 |
Tangible Book Value Per Share | -16.44 | -27.34 | -71.22 | -96.70 | -54.13 | 113.66 |
Machinery | - | - | - | 0.26 | 0.29 | 0.28 |
Construction In Progress | - | - | - | - | - | 0.02 |
Leasehold Improvements | - | - | - | 0.06 | 0.06 | 0.09 |